[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541241":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":41,"centralContacts":57,"locations":64,"responsibleParty":84,"collaborators":41,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":41,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":41,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":41,"overallStatus":67,"whyStopped":41,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"AmtixBio Co., Ltd.","INDUSTRY",[8,14,19,24,29],{"label":9,"type":10,"description":11,"interventionNames":12},"ATB1651-102 Cohort 1","EXPERIMENTAL","The planned ATB1651 dose of 3% solution to each infected toenail once daily for 12 weeks (follow up for 24 weeks) Twenty-five participants are expected to enroll per cohort.",[13],"Drug: ATB1651-102- Cohort 1",{"label":15,"type":10,"description":16,"interventionNames":17},"ATB1651-102 Cohort 2","The planned ATB1651 dose of 3% solution to each infected toenail once daily for 20 weeks follow up for 16 weeks) Twenty-five participants are expected to enroll per cohort.",[18],"Drug: ATB1651-102- Cohort 2",{"label":20,"type":10,"description":21,"interventionNames":22},"ATB1651-102 Cohort 3","The planned ATB1651 dose of 3% solution to each infected toenail twice daily for 12weeks follow up for 24 weeks).\n\nTwenty-five participants are expected to enroll per cohort.",[23],"Drug: ATB1651-102- Cohort 3",{"label":25,"type":10,"description":26,"interventionNames":27},"ATB1651-102 Cohort 4","The planned ATB1651 dose of 5% solution to each infected toenail once daily for 12weeks follow up for 24 weeks).\n\nTwenty-five participants are expected to enroll per cohort.",[28],"Drug: ATB1651-102- Cohort 4",{"label":30,"type":31,"description":32,"interventionNames":33},"Placebo","PLACEBO_COMPARATOR","Matching placebo to the IP per cohort.\n\nFive participants are expected to be enrolled per cohort.",[34],"Drug: Placebo",[36,42,46,50,54],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","ATB1651-102- Cohort 1","Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.",[9],null,{"type":37,"name":43,"description":44,"armGroupLabels":45,"otherNames":41},"ATB1651-102- Cohort 2","Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.",[15],{"type":37,"name":47,"description":48,"armGroupLabels":49,"otherNames":41},"ATB1651-102- Cohort 3","Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.",[20],{"type":37,"name":51,"description":52,"armGroupLabels":53,"otherNames":41},"ATB1651-102- Cohort 4","Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.",[25],{"type":37,"name":30,"description":55,"armGroupLabels":56,"otherNames":41},"participants will receive matching placebo across cohorts 1-4 of the study.",[30],[58],{"name":59,"role":60,"phone":61,"phoneExt":62,"email":63},"Jason (Jong-Seung) Lee","CONTACT","31 5175 8215","+82","jason_lee@amtixbio.com",[65],{"facility":66,"status":67,"city":68,"state":41,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"New Zealand Clinical Research Christchurch","RECRUITING","Christchurch","8011","New Zealand","NZ",{"type":73,"coordinates":74},"Point",[75,76],172.63333,-43.53333,{"lat":76,"lon":75},[79,82],{"name":80,"role":60,"phone":81,"phoneExt":41,"email":41},"Corey Sellwood, Dr","+64 800 862 278",{"name":80,"role":83,"phone":41,"phoneExt":41,"email":41},"PRINCIPAL_INVESTIGATOR",{"type":85,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100541241","phase-2-a-study-of-atb1651-in-adults-with-mild-to-moderate-onchomycosis-100541241",false,"NCT06327295","A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the","Inclusion Criteria:\n\n1. Confirmation of onychomycosis by positive mycological (KOH) staining and positive culture from affected great toenail(s).\n2. Appearance of onychomycosis involving 20% to 60% of 1 (or both) affected great toenail(s), as determined by visual inspection after the nail has been trimmed. If the percentage of infection is outside this range but is still considered appropriate for this study, based on the overall impression of the Principal Investigator (PI), participation can be considered in consultation with the Medical Monitor (MM). The visual inspection results of the appearance of onychomycosis involving 20% to 60% of 1 (or both) affected great toenail(s) will be reviewed by the Sponsor before enrollment.\n3. The combined thickness of the distal nail plate at the associated hyperkeratotic nail bed is \\\u003C 2 mm.\n4. Adult males and females, 18 to 70 years of age (inclusive) at the time of Screening.\n5. In good general health, with no significant medical history, and no clinically significant abnormalities on physical examination or ECG at Screening and\u002For before the first administration of IP at the discretion of the PI or designee. Participants with mild stable disease may be considered eligible at the discretion of the PI or designee.\n6. Body mass index (BMI) between 17.5 and 35.0 kg\u002Fm2, inclusive, at Screening.\n\nExclusion Criteria:\n\n1. History of allergy to any of the excipients in ATB1651.\n2. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at Screening or Day 1.\n3. Underlying physical or psychological medical conditions that, in the opinion of the PI, would make it unlikely for the participant to comply with the protocol or complete the study per protocol.\n4. Unwilling to refrain from the use of nail cosmetics such as clear and\u002F or colored nail lacquers from the Screening visit until the end of the study.\n5. Use of any IP or investigational medical device within 30 days prior to Screening, or 5 half-lives of the product (whichever is the longest) or participation in more than 4 investigational drug studies within 1 year prior to Screening.\n6. Diabetes mellitus requiring treatment other than diet and exercise.","ALL","18 Years","70 Years",{"count":97,"type":98},120,"ESTIMATED","INTERVENTIONAL",[101],"PHASE2","The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis",[104],"Onychomycosis","2025-02-17",{"date":107,"type":108},"2025-02-19","ACTUAL",{"date":110,"type":108},"2024-07-01",{"date":112,"type":98},"2026-01-30",{"name":5,"class":6},1]